Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral cladribine in clinically isolated syndrome at high risk of multiple sclerosis
2008-003706-33Phase 3Terminated
- Sponsor
- Merck Serono
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) and clinically isolated syndrome (CIS) comparing Cladribine with Placebo (2 arms). Primary endpoint: Time to conversion to clinically definite multiple sclerosis. Started Oct 2008; status: terminated.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2008-003706-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003706-33.